Anthrax Immune Globulin Intravenous (Human) (Anthrasil)
Anthrax Immune Globulin Intravenous (Human) is an FDA-licensed reference biologic from Emergent BioSolutions Canada Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2015
Reference approved
Reference product
Anthrasil Anthrax Immune Globulin Intravenous (Human)
Emergent BioSolutions Canada Inc.
- Approved
- Mar 24, 2015
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Anthrax Immune Globulin Intravenous (Human), in chronological order.
Reference approval
Approval date of the reference Anthrax Immune Globulin Intravenous (Human) product.
11 yr 4 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
4 yr 3 mo ago
Frequently asked questions
Are there biosimilars approved for Anthrax Immune Globulin Intravenous (Human) (Anthrasil)?
No 351(k) biosimilars or interchangeable biosimilars referencing Anthrax Immune Globulin Intravenous (Human) are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.